Impact of Primary Open-Angle Glaucoma: Early Diagnosis and Timely Treatment
Main Article Content
Abstract
Glaucoma is the leading cause of irreversible blindness worldwide and it is important to assess the impact of timely diagnosis and treatment on this disease due to the complications it can bring to patients. It is an insidious pathology and sometimes it is usually detected spontaneously in ordinary consultations. The most frequent type of glaucoma is primary open-angle glaucoma (POAG), being the second cause of blindness worldwide according to the WHO. Making known and providing information on the subject can reduce cases of blindness in the world and patients could lead a better quality of life by going to the doctor in time knowing how to identify the pathology through its clinical picture in early stages.
Glaucoma is the leading cause of irreversible blindness worldwide. It is an insidious pathology that is usually detected spontaneously. The most common type is the open angle primary (OPAG). It is important to know and provide information in order to detect and prevent cases of blindness in the world.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Riordan, P., & cunningham, E. (2012). Vaughan y Asbury. Oftalmología general (8th ed.). McGRAW-HILL.
II. En Mexico, cerca de 1.5 millones de personas tienen glaucoma. (s. f.). Recuperado 17 de octubre de 2022, de https://www.dgcs.unam.mx/boletin/bdboletin/2020_221.html
III. Distelhorst, J. S. (2003, 1 mayo). Open-Angle Glaucoma. AAFP. Recuperado 17 de octubre de 2022, de
https://www.aafp.org/pubs/afp/issues/2003/0501/p1937.html
IV. Graue, E. (2019, 13 agosto). Oftalmología en la práctica de la medicina general (5.a ed.). McGraw-Hill.
V. Papadakis, M. A. (2022, 19 octubre). DIAGNÓSTICO CLÍNICO Y TRATAMIENTO / 54 ED. MC GRAW HILL.
VI. Pleet A, Sulewski M, Salowe RJ, Fertig R, Salinas J, Rhodes A, Merritt Iii W, Natesh V, Huang J, Gudiseva HV, Collins DW, Chavali VR, Tapino P, Lehman A, Regina-Gigiliotti M, Miller-Ellis E, Sankar P, Ying GS, O'Brien JM. Risk Factors Associated with Progression to Blindness from Primary Open-Angle Glaucoma in an African-American Population. Ophthalmic Epidemiol. 2019 Aug;23(4):248-56.
doi: 10.1080/09286586.2016.1193207. Epub 2016 Jun 27. PMID: 27348239; PMCID: PMC4939437.
VII. Fan BJ, Bailey JC, Igo RP Jr, Kang JH, Boumenna T, Brilliant MH, Budenz DL, Fingert JH, Gaasterland T, Gaasterland D, Hauser MA, Kraft P, Lee RK, Lichter PR, Liu Y, Moroi SE, Myers JS, Pericak-Vance MA, Realini A, Rhee DJ, Richards JE, Ritch R, Schuman JS, Scott WK, Singh K, Sit AJ, Vollrath D, Weinreb RN, Wollstein G, Zack DJ, Haines JL, Pasquale LR, Wiggs JL. Association of a Primary Open-Angle Glaucoma Genetic Risk Score With Earlier Age at Diagnosis. JAMA Ophthalmol. 2019 Oct 1;137(10):1190-1194.
doi: 10.1001/jamaophthalmol.2019.3109.
PMID: 31436842; PMCID: PMC6707005.
VIII. Aboobakar IF, Wiggs JL. The genetics of glaucoma: Disease associations, personalised risk assessment and therapeutic opportunities-A review. Clin Exp Ophthalmol. 2022, Mar;50(2):143-162. doi: 10.1111/ceo.14035. Epub 2022 Jan 17. PMID: 35037362; PMCID: PMC9185665.
IX. Aspberg, J., Heijl, A. & Bengtsson, B. (2021, agosto). Screening for Open-Angle Glaucoma and Its Effect on Blindness. American Journal of Ophthalmology, 228, 106-116.
https://doi.org/10.1016/j.ajo.2021.03.030.
X. Martínez, N., Martínez, N., Acosta, R. & Castillo, R. (2019). El glaucoma primario de ángulo abierto, caracterización clínica en Pinar del Río. Scielo.sld.cu. http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-31942019000600810.
XI. Padilla, G. J. M. C., Teherán, O. F. & Ochoa, M. (2021). Evaluación de la triple combinación bimatoprost/brimonidina/timolol en el control de la presión intraocular en pacientes con glaucoma. UNIVERSIDAD DEL SINU SECCIONAL CARTAGENA
XII. Royer, C. (2019). Latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: systematic literature review and network meta-analysis. Value in Health, Sensory System Disorders - Clinical outcomes. S363. PeriPharm inc, Montreal, QC, Canada. University of Montreal.
XIII. Dove Press. (2021, marzo 2). Real-World Study on Patient Satisfaction and Tolerability After Switch | OPTH. Recuperado 18 de octubre de 2022, de https://www.dovepress.com/real-world-study-on-patient-satisfaction-and-tolerability-after-switc h-peer-reviewed-fulltext-article-OPTH.
XIV. Vista de Efectividad de trabeculoplastia láser diodo micropulso en pacientes sin tratamiento previo: estudio retrospectivo con seguimiento de 12 meses. (s. f.). Recuperado 19 de octubre de 2022, de https://www.revistaoce.com/index.php/revista/article/view/167/269
XV. Gazzard, G. (2019). Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Pubmed. Recuperado 19 de octubre de 2022, de
https://pubmed.ncbi.nlm.nih.gov/30862377/
XVI. Vajaranant, T. S. et al. A. J. O. (2018). Racial Differences in the Effects of Hormone Therapy on Incident Open-Angle Glaucoma in a Randomized Trial. Pubmed. Recuperado 19 de octubre de 2022, dehttps://pubmed.ncbi.nlm.nih.gov/30081016/
XVII. Kastner A, King AJ. Advanced glaucoma at diagnosis: current perspectives. Eye (Lond). 2020 Jan;34(1):116-128. doi: 10.1038/s41433-019-0637-2. Epub 2019 Nov 18. PMID: 31740802; PMCID: PMC7002722.